Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Eisai Stories

2012-06-22 06:22:40

WOODCLIFF LAKE, N.J., June 22, 2012 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Shaji Procida to the position of Vice President and Chief Financial Officer. Previously, Ms. Procida held the position of Vice President of Finance. In her elevated role, she will have oversight and responsibility for all of Eisai's financial operations in the United States. In addition, she will continue to serve as a member of...

2012-05-15 02:28:29

EMERYVILLE, Calif., May 15, 2012 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss the proposed safety and efficacy studies to be conducted for the registration of Arimenda (memantine HCl extended release and donepezil HCl) capsules. Arimenda, a once-daily fixed dose combination of extended release memantine and donepezil, is being developed for the treatment of moderate-to-severe...

2012-05-10 14:22:28

SAN DIEGO and WOODCLIFF LAKE, N.J., May 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. Lorcaserin is an investigational drug candidate intended for weight management. In addition to the United States, the territories in the expanded agreement now include most of...

2012-04-30 02:26:03

WOODCLIFF LAKE, N.J., April 30, 2012 /PRNewswire/ -- Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Allen Waxman to the position of Senior Vice President and General Counsel. In this position, Mr. Waxman will lead the Office of the General Counsel, where he will be responsible for all legal matters for the company in the U.S. Mr. Waxman will be a member of the company's Executive Committee and will also join others in providing leadership for...

2012-04-23 20:20:01

Tokyo, Apr 23, 2012 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) that the condition for approval of Humira(R) pre-filled syringe 40 mg/0.8 mL for subcutaneous injection (adalimumab [genetical recombination]), a fully human anti-TNF-alpha monoclonal antibody, has been lifted in terms of a drug use results survey (all-case surveillance) for plaque psoriasis and...

2012-04-19 18:20:20

WOODCLIFF LAKE, N.J., April 20, 2012 /PRNewswire/ -- Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku Co., Ltd., pertaining to exclusive overseas marketing rights for the Aricept® patch (once weekly donepezil HCl transdermal system). (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) The amendment allows TPU to be solely responsible for making all decisions regarding future...

2012-04-18 10:24:44

WOODCLIFF LAKE, N.J., April 18, 2012 /PRNewswire/ -- Eisai Inc. announced today that the results of the study, "Randomized Phase III Study 306: Adjunctive Perampanel for Refractory Partial-Onset Seizures," were published online today in the April 18, 2012, edition of Neurology®. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) Marketing authorization applications for perampanel are currently under review with the U.S. Food and Drug Administration and the...

2012-04-16 02:28:44

EXTON, Pa., April 16, 2012 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 in the treatment of metastatic colorectal cancer that is refractory to all standard therapy. MORAb-004 is a monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1). The trial is a randomized, double-blind, placebo-controlled study to assess the...

2012-04-03 08:20:02

Tokyo, Apr 3, 2012 - (JCN Newswire) - Eisai Co., Ltd. and its diagnostics subsidiary EIDIA Co., Ltd. announced today that EIDIA entered into two separate agreements with medical equipment manufacturers Toshiba Medical Systems Corporation and GE Healthcare Japan Corporation on April 2 for Japan sales of PROTOCO2L, a carbon dioxide insufflation system for CT (computed tomographic) colonography, and carbon dioxide insufflation tube PROTOCO2L Catheter Set (collectively referred to as "the...

2012-03-23 11:15:50

Observations: How the FDA forgot the evidence: The case of donepezil 23 mg Approval for a new dose of a best-selling Alzheimer's drug "breached the FDA's own regulatory standard" and has led to "incomplete and distorted messages" about the drug, warn experts on bmj.com today. In the first of a new occasional series, "not so", highlighting the exaggerations, distortions, and selective reporting that mark some news stories, advertising, and medical journal articles, Lisa M. Schwartx and...